Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00539 ...
Drug Name Toremifene
Molecular Weight 405.96
Molecular Formula C26H28ClNO
CAS Number 89778-26-7
SMILES CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1
External Links
DRUGBANK DB00539
PubChem Compound 3005573
PDR 716
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 6.8 - 6.8 - DRUGBANK
Melting Point 109.0 ℃ 108-110 ℃ DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
C Max 1200.0 ng/ml 1.1-1.3 mcg/ml PO, oral; adults; breast cancer; The Pharmacological Basis of Therapeutics
C Max 4250.0 ng/ml 2.7-5.8 mcg/ml PO, oral; adults; breast cancer; The Pharmacological Basis of Therapeutics
T Max 2.3 h 1.5-3 h PO, oral; adults; breast cancer; The Pharmacological Basis of Therapeutics
T Max 4.5 h 3-6 h PO, oral; adults; breast cancer; The Pharmacological Basis of Therapeutics
Clearance 2.0 L/h 5.0 L/h DRUGBANK
Clearance 2.6 L/h/m2 2.6±1.2 L/h/m2 apparent clearance; PO, oral; Male, men;  Female, women; patients;  Female, women; hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 580.0 L 580.0 L DRUGBANK
Volume of Distribution 479.0 L/m2 479±154 L/m2 Apparent volume of distribution; PO, oral; Male, men;  Female, women; patients;  Female, women; Elderly ↑ ; The Pharmacological Basis of Therapeutics
Half-life 120.0 h 5 day DRUGBANK
Half-life 148.0 h 148±53 h PO, oral; chronic liver disease ↑ ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 504.0 h 504±578 h PO, oral; Metabolite; The Pharmacological Basis of Therapeutics
Eliminate Route 0 % ~0 % Urinary excretion; adults; Male, men;  Female, women;  Female, women; breast cancer; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 92.0 % 92 % DRUGBANK
Protein Binding 2.0 % 2 % DRUGBANK
Protein Binding 99.7 % 99.7 % adults; normal,healthy;  Female, women; breast cancer; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adults 60.0 mg/day 60 mg/day PO, oral Fareston toremifene citrate PDR
Max dose for geriatric 60.0 mg/day 60 mg/day PO, oral Fareston toremifene citrate PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1